X4 PHARMACEUTICALS, INC Accounts Payable
X4 PHARMACEUTICALS, INC (XFOR) had Accounts Payable of $3.93 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable, Current $3.93M.
- 2026-03-31: Accounts Payable, Current $5.07M.
- 2025-12-31: Accounts Payable, Current $5.70M.
- 2025-09-30: Accounts Payable, Current $5.05M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.93M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $5.70M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $5.05M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $7.71M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $11.12M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $8.62M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $8.58M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $7.99M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $8.94M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $8.95M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $8.13M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $5.11M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $5.99M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $7.78M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $3.80M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $3.68M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $3.57M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $4.28M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $2.42M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $2.53M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $3.09M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $3.14M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $3.89M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $1.84M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $1.25M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $2.09M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $1.70M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $3.10M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $6.13M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $2.97M 10-K · filed 2020-03-12 | $545.00K 10-K · filed 2019-03-11 |
| 2018-09-30 | $2.13M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $2.14M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $1.11M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.89M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |